# RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

> **NCT07266545** · PHASE4 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 120 (estimated)

## Conditions studied

- Unipolar Depression
- Bipolar Depression

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Bupropion extended release
- **DRUG:** Cariprazine (Augmentation Phase)

## Key facts

- **NCT ID:** NCT07266545
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-17
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266545, "RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07266545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*